Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | I-BET151 + SGC0946 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| I-BET151 | GSK1210151A | BRD3 Inhibitor 2 BRD4 Inhibitor 11 | I-BET151 is a small molecule that blocks Brd3/4 binding to chromatin, resulting in transcription inhibition and potentially leading to tumor cell death (PMID: 21964340, PMID: 30906568, PMID: 32603665). | |
| SGC0946 | DOT1L Inhibitor 3 | SGC0946 inhibits DOT1L, resulting in reduced viability of leukemia cells with MLL fusions (PMID: 23250418, PMID: 28209620). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KMT2A fusion | acute myeloid leukemia | sensitive | I-BET151 + SGC0946 | Preclinical - Patient cell culture | Actionable | In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A fusions in culture (PMID: 27294782). | 27294782 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|